Search Results

Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution.

• Authors : Pepose, Jay S.^1,2 (AUTHOR); Wirta, David³ (AUTHOR); Evans, David⁴ (AUTHOR)

• Source: Ophthalmology. Jan2025, Vol. 132 Issue 1, p79-91. 13p.

Record details

INTERNATIONAL PATENT: OCUPHIRE PHARMA, INC. FILES APPLICATION FOR "METHODS AND COMPOSITIONS FOR PREVENTING THE PROGRESSION OF DIABETIC RETINOPATHY AND RELATED CONDITIONS"

• Source: US Fed News (USA), August 6, 2024, 2pp

Record details

Patent Application Titled 'Methods And Compositions For Treating Mydriasis, Glaucoma, And Other Ocularconditions' Published Online (USPTO 20240216334)

• Source: Obesity, Fitness & Wellness Week. July 27, 2024, 654

Record details

Patent Application Titled "Methods And Compositions For Treating Mydriasis, Glaucoma, And Other Ocularconditions" Published Online (USPTO 20240216334).

Subjects: PATENT applications; INVENTORS; MYDRIASIS

• Source: Pharma Business Week; 7/26/2024, p3249-3249, 1p

Record details

Patent Issued for Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders (USPTO 12016841).

Subjects: INVENTORS; MYDRIASIS; PRESBYOPIA

• Source: Pharma Business Week; 7/16/2024, p3818-3818, 1p

Record details

Researchers Submit Patent Application, "Methods And Compositions For Treatment Of Mydriasis", for Approval (USPTO 20230040217).

Subjects: PATENT applications; MYDRIASIS; CARDIOVASCULAR agents

• Source: Pharma Business Week; 3/3/2023, p4000-4000, 1p

Record details

Researchers Submit Patent Application, "Methods And Compositions For Treatment Of Mydriasis", for Approval (USPTO 20230032637).

Subjects: PATENT applications; MYDRIASIS; CARDIOVASCULAR agents

• Source: Pharma Business Week; 2/24/2023, p2988-2988, 1p

Record details

8-K: Ocuphire Pharma, Inc.

• Source: EDGAR Online 8-K Glimpse (USA), January 25, 2023, 11pp

Record details

8-K: Ocuphire Pharma, Inc.

• Source: EDGAR Online 8-K Glimpse (USA), December 6, 2022, 6pp

Record details

Ocuphire Pharma Inc Update Call - Final

• Source: Fair Disclosure Wire (Quarterly Earnings Reports). 11/08/2022.

Record details